Literature DB >> 8639485

Molecular cloning and functional expression of a new human CC-chemokine receptor gene.

M Samson1, O Labbe, C Mollereau, G Vassart, M Parmentier.   

Abstract

The cloning of several receptors activated by either CC or CXC chemokines and belonging to the G protein-coupled family of receptors has been reported recently. In the present work, we describe the cloning of a human gene, named ChemR13, encoding a new CC-chemokine receptor. The gene encodes a protein of 352 amino acids with a calculated molecular mass of 40 600 Da and displaying a single potential site for N-linked glycosylation. Using a set of overlapping lambda clones, the genomic organisation of the locus was investigated, demonstrating that the ChemR13 gene is physically linked, and in the same orientation, as the CC-CKR2 gene that encodes a receptor for the monocyte chemoattractant protein-1 (MCP-1). A distance of 17.5 kb separates the two coding regions, which share 75% identity in nucleic acid and amino acid sequences. Human ChemR13 was functionally expressed in a stably transfected CHO-K1 cell line. Physiological responses to chemokines were monitored using a microphysiometer. Macrophage inflammatory protein 1 alpha (MIP-1 alpha) was the most potent agonist. MIP-1 beta and RANTES were also active at physiological concentrations. The other CC-chemokines, MCP-1, MCP-2 and MCP-3, as well as CXC-chemokines (IL-8, GRO alpha) had no effect. ChemR13 receptor transcripts were detected by Northern blotting in the promyeloblastic cell line KG-1A, suggesting a potential role in the control of granulocytic lineage proliferation or differentiation. ChemR13 is thus a new member of the growing family of chemokine receptors that mediate the recruitment of cells involved in immune and inflammatory processes. Being the fifth functionally identified receptor in his class, this new CC-chemokine receptor (CC-CKR) is tentatively designated CC-CKR5.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639485     DOI: 10.1021/bi952950g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  171 in total

1.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Pharmacological characterization of the chemokine receptor, CCR5.

Authors:  Anja Mueller; Nasir G Mahmoud; Marc C Goedecke; Jane A McKeating; Philip G Strange
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  High frequency of the HIV-1 protective CCR5 delta32 deletion in native Estonians.

Authors:  I Kalev; A V Mikelsaar; L Beckman; G Tasa; P Pärlist
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

5.  High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.

Authors:  M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

6.  Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.

Authors:  P A Zimmerman; A Buckler-White; G Alkhatib; T Spalding; J Kubofcik; C Combadiere; D Weissman; O Cohen; A Rubbert; G Lam; M Vaccarezza; P E Kennedy; V Kumaraswami; J V Giorgi; R Detels; J Hunter; M Chopek; E A Berger; A S Fauci; T B Nutman; P M Murphy
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

7.  Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials.

Authors:  S J Prest; R C Rees; C Murdoch; J F Marshall; P A Cooper; M Bibby; G Li; S A Ali
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

8.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

9.  Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.

Authors:  Sujatha Iyengar; David H Schwartz
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

10.  Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.

Authors:  Christoph Seibert; Martine Cadene; Anthony Sanfiz; Brian T Chait; Thomas P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.